Tags

Type your tag names separated by a space and hit enter

RETRACTED ARTICLE

Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients.
J Cardiothorac Vasc Anesth. 2001 Jun; 15(3):316-21.JC

Abstract

OBJECTIVE

To compare volume therapy with HES 130/0.4, a new hydroxyethylstarch (HES) solution with a gelatin-based fluid replacement strategy.

DESIGN

Prospective, randomized, safety study.

SETTING

Urban, university-affiliated hospital (single institution).

PARTICIPANTS

Forty-two patients undergoing elective cardiac surgery.

INTERVENTIONS

Patients were prospectively randomized into 2 groups: In group 1 (n = 21), gelatin was given perioperatively for volume support until the 1st postoperative day to keep the central venous pressure (CVP) between 10 and 14 mmHg; in group 2 (n = 21) HES 130/0.4 was administered using the same protocol as in group 1.

MEASUREMENTS AND MAIN RESULTS

Standard coagulation variables and modified thromboelastography (TEG) were used. Using different activators for extrinsic and intrinsic activation and heparin inactivation by heparinase, the onset of coagulation (coagulation time), kinetics of clot formation (clot formation time), and maximum clot firmness were measured. Measurements were performed after induction of anesthesia (T0), at the end of surgery (T1), 4 hours after surgery (T2), and on the morning of the 1st postoperative day (T3). A total of 3310 +/- 810 mL of gelatin and 3070 +/- 570 mL of HES 130/0.4 were used in the 2 groups during the study period. The 2 groups did not differ with regard to postoperative bleeding or in use of packed red blood cells or fresh frozen plasma. Standard coagulation variables were similar between the 2 groups. All TEG variables were within the normal range at baseline. Coagulation time and clot formation time data were significantly elevated after surgery and in the intensive care unit, without showing specific differences between the 2 volume replacement groups. Intrinsic TEG and heparinase TEG clot formation times remained significantly higher until the end of the study period. No differences were seen between HES-treated and gelatin-treated patients.

CONCLUSIONS

Volume replacement with the new HES preparation was as safe as gelatin-based volume replacement with regard to coagulation in cardiac surgical patients. HES 130/0.4 is an alternative plasma substitute to treat volume deficits.

Authors+Show Affiliations

Department of Anesthesiology and Intensive Care Medicine, and Clinic of Cardiac Surgery, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Retracted Publication

Language

eng

PubMed ID

11426361

Citation

Haisch, G, et al. "Influence of a New Hydroxyethylstarch Preparation (HES 130/0.4) On Coagulation in Cardiac Surgical Patients." Journal of Cardiothoracic and Vascular Anesthesia, vol. 15, no. 3, 2001, pp. 316-21.
Haisch G, Boldt J, Krebs C, et al. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth. 2001;15(3):316-21.
Haisch, G., Boldt, J., Krebs, C., Suttner, S., Lehmann, A., & Isgro, F. (2001). Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. Journal of Cardiothoracic and Vascular Anesthesia, 15(3), 316-21.
Haisch G, et al. Influence of a New Hydroxyethylstarch Preparation (HES 130/0.4) On Coagulation in Cardiac Surgical Patients. J Cardiothorac Vasc Anesth. 2001;15(3):316-21. PubMed PMID: 11426361.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. AU - Haisch,G, AU - Boldt,J, AU - Krebs,C, AU - Suttner,S, AU - Lehmann,A, AU - Isgro,F, PY - 2001/6/27/pubmed PY - 2001/8/17/medline PY - 2001/6/27/entrez SP - 316 EP - 21 JF - Journal of cardiothoracic and vascular anesthesia JO - J Cardiothorac Vasc Anesth VL - 15 IS - 3 N2 - OBJECTIVE: To compare volume therapy with HES 130/0.4, a new hydroxyethylstarch (HES) solution with a gelatin-based fluid replacement strategy. DESIGN: Prospective, randomized, safety study. SETTING: Urban, university-affiliated hospital (single institution). PARTICIPANTS: Forty-two patients undergoing elective cardiac surgery. INTERVENTIONS: Patients were prospectively randomized into 2 groups: In group 1 (n = 21), gelatin was given perioperatively for volume support until the 1st postoperative day to keep the central venous pressure (CVP) between 10 and 14 mmHg; in group 2 (n = 21) HES 130/0.4 was administered using the same protocol as in group 1. MEASUREMENTS AND MAIN RESULTS: Standard coagulation variables and modified thromboelastography (TEG) were used. Using different activators for extrinsic and intrinsic activation and heparin inactivation by heparinase, the onset of coagulation (coagulation time), kinetics of clot formation (clot formation time), and maximum clot firmness were measured. Measurements were performed after induction of anesthesia (T0), at the end of surgery (T1), 4 hours after surgery (T2), and on the morning of the 1st postoperative day (T3). A total of 3310 +/- 810 mL of gelatin and 3070 +/- 570 mL of HES 130/0.4 were used in the 2 groups during the study period. The 2 groups did not differ with regard to postoperative bleeding or in use of packed red blood cells or fresh frozen plasma. Standard coagulation variables were similar between the 2 groups. All TEG variables were within the normal range at baseline. Coagulation time and clot formation time data were significantly elevated after surgery and in the intensive care unit, without showing specific differences between the 2 volume replacement groups. Intrinsic TEG and heparinase TEG clot formation times remained significantly higher until the end of the study period. No differences were seen between HES-treated and gelatin-treated patients. CONCLUSIONS: Volume replacement with the new HES preparation was as safe as gelatin-based volume replacement with regard to coagulation in cardiac surgical patients. HES 130/0.4 is an alternative plasma substitute to treat volume deficits. SN - 1053-0770 UR - https://www.unboundmedicine.com/medline/citation/11426361/Influence_of_a_new_hydroxyethylstarch_preparation__HES_130/0_4__on_coagulation_in_cardiac_surgical_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1053-0770(01)11538-7 DB - PRIME DP - Unbound Medicine ER -